Effectiveness of Ustekinumab for Patients With Moderate-to-Severe Ulcerative Colitis: A Multicenter Real-World Canadian Study.

INTRODUCTION

We aimed to evaluate the real-world effectiveness and safety of ustekinumab for the treatment of both bio-naive and bio-exposed ulcerative colitis patients in a real-world setting.

METHODS

Retrospective, Canadian multicenter cohort study. Primary outcomes were clinical remission and endoscopic remission. Key secondary outcomes included composite clinical and endoscopic response, safety, and persistence. Univariable logistic regression was conducted to examine associations between baseline factors and 12-month clinical and endoscopic response and remission. The primary focus was on the association between these outcomes and bioexposure status.

RESULTS

A total of 198 patients were included, of whom 47.5% were female and 85.9% were younger than 65 years. The majority had severe endoscopic activity at baseline (47.5%, n = 87) and were bio-exposed (88.8%, n = 176; 33%, n = 66 previous failure of 3 or more biologics). Patients were followed for a median of 12.8 (interquartile range 8.2-22.1) months after induction. The overall clinical remission rates were 41.3% (69/167), 38.1% (56/147), and 43.6% (58/133) at 3, 6 and 12 months, respectively. Endoscopic remission rates (Mayo endoscopy score = 0) were 8.0% (7/88), 18.7% (23/123), and 12.5% (11/88) at 3, 6, and 12 months, respectively, and consistently higher in bio-naive patients compared with bio-exposed patients through 12 months ( P < 0.05 at all time points). Bio-naive patients were more likely to achieve endoscopic remission compared with bio-exposed (hazard ratio = 5.40, 95% confidence interval [CI]: 1.08-26.93). Adverse events were reported in 14.1% (18/198).

DISCUSSION

In a highly refractory and largely bio-exposed population, a substantial proportion of patients with ulcerative colitis treated with ustekinumab can achieve clinical and endoscopic outcomes of importance after 12 months. Previous biologic exposure is associated with lower rates of endoscopic remission.